Serputinib/Serpatinib (Ruitu) standard usage and dosage instructions

Selpercatinib is a new highly selective RET kinase inhibitor developed by Eli Lilly for the treatment of multiple tumor types with RET gene abnormalities, including RET fusion-positive non-small cell lung cancer (NSCLC), thyroid cancer (TC) and RET-mutant medullary thyroid cancer (MTC). Abnormal RET genes have been found in a variety of cancers, driving abnormal cell proliferation, evading immune clearance, and promoting tumor progression. Serputinib blocks this oncogenic signal at the molecular level by targeting the RET pathway, providing patients with more targeted targeted treatment options.

Seputinib is administered as an oral preparation, and the dosage regimen is individually adjusted based on the patient's weight. For patients weighing less than 50 kg, the recommended dose is 120 mg orally twice daily, while patients weighing 50 kg and above should use 160 mg twice daily, approximately every 12 hours. The tablet should be swallowed whole, with or without food, but grapefruit or its products should be avoided at the same time, as these foods may affect drug metabolism. Treatment should be continued until disease progression or intolerable toxicity occurs. Doctors usually adjust the dose based on the patient's tolerance and blood drug concentration to ensure a balance between efficacy and safety.

In clinical practice, seputinib is usually used in patients who are confirmed positive byRET test, so it is crucial to conduct genetic testing before taking the drug. For patients receiving this drug, doctors regularly monitor liver function, blood pressure, and electrolyte levels to prevent potential adverse effects. Common adverse reactions of seputinib include mild diarrhea, fatigue, dry mouth, and increased blood pressure, which can usually be managed through dose adjustment or supportive care. Different from traditional chemotherapy, seputinib has higher target specificity and can maintain strong anti-tumor activity while reducing systemic toxicity.

Reference:https://en.wikipedia.org/wiki/Selpercatinib